Evidence map›Paper›PMID 40837613›Full record

ArticleIDCases2025

Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report.

Anum Hamiduzzaman, Jean Hou, Tram Higgins, Pryce Gaynor, Abhirami Shankar, Erik L Lum

Abstract readCase Reports
In one paragraph

Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anum HamiduzzamanDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Jean HouDepartment of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Tram HigginsDepartment of Transplant Services, Kidney and Pancreas Transplant. UCLA. Los Angeles, CA 90095, USA.
Pryce GaynorDivision of Infectious Disease, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Abhirami ShankarHarbor UCLA Medical Center Division of Nephrology, Los Angeles, CA 90502, USA.
Erik L LumDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BK Polyomavirus (BKPyV) is an important risk factor for premature graft loss following kidney transplant. Current practice guidelines recommend screening for BK virus DNA for 2 years after kidney transplant as the risk of BK Polyomavirus associated nephropathy (BKPyVAN) wanes over time. This case report presents a unique scenario of late onset BKPyVAN 15 years following kidney transplant precipitated by administration of chemotherapy to treat multiple myeloma. A woman in her 60 s with no prior history of BKPyV was diagnosed with multiple myeloma 14 years after kidney transplant. Her immunosuppression was tapered to tacrolimus and prednisone before undergoing chemotherapy treatment for her multiple myeloma. Although the chemotherapy was effective in achieving remission of her myeloma, she developed worsening renal dysfunction without proteinuria. Kidney biopsy revealed positive SV40 staining and subsequent BK DNA serum PCR was found to be 236,000 copies/mL suggestive of BKPyVAN. Although incredibly rare, late onset BKPyVAN should be considered as a cause of sustained elevation in serum creatinine, new onset proteinuria, or new onset hematuria in kidney transplant recipients who have experienced an augmentation in immunosuppression such as patients undergoing chemotherapy for underlying malignancies.

Indexed as

BK nephropathyKidney TransplantMultiple Myeloma

Identifiers

PMID40837613
PMCPMC12362014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.